Advanced glycation end products in patients with peripheral artery disease or abdominal aortic aneurysms

Advanced glycation end products in patients with peripheral artery disease or abdominal aortic aneurysms - ARTERY study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45188

Enrollment

180

Registered

2015-07-10

Start date

2016-04-21

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral artery disease - atherosclerosis of the leg

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age above 18 years old. Written informed consent for study participation. Proven PAD or AAA PAD: patients planned for a bypass surgery or endarterectomy of the lower arteries, and/or: AAA: patients planned for an open repair of the aneurysm.

Exclusion criteria

Exclusion criteria: Patients not able or willing to sign informed consent. rheumatoid arthritis, systemic lupus erythematosus, Giant Cell Arteritis, retroperitoneal fibrosis, Takayasu arteritis or any other systemic inflammatory disorder. Patients with Ehlers-Danlos syndrom or Marfan syndrom Patients with signs of an inflammatory or mycotic aneurysm (on computed tomographic angiography).

Design outcomes

Primary

Measure	Time frame
The primary objective is to compare the amount, type and localisation of AGEs of the arterial wall of PAD, AAA and PAD+AAA between patients with and without diabetes mellitus.	—

Secondary

Measure	Time frame
The secondary objectives are to explore the association between AGEs content of the arterial wall of PAD, AAA and PAD+AAA patients and (1) serum, urine and skin AGEs, (2) in vivo and in vitro mechanical properties of the arterial wall and (3) serum, urine and tissue markers of inflammation and oxidative stress.	—

Countries

Netherlands

Outcome results